Myelopeptide-2 (MP-2) Mechanisms, Clinical Value, and Resear

Myelopeptide-2 (MP-2): Mechanisms, Clinical Value, and Research Perspectives in Immunomodulation
Introduction [Related: y 27632 dihydrochloride]
Myelopeptide-2 (MP-2) is a synthetic immunomodulatory peptide derived from endogenous myelopeptides, a class of regulatory peptides originally isolated from human bone marrow. MP-2 has garnered significant attention due to its potent immunoregulatory properties, particularly its ability to modulate cytokine production and influence immune cell differentiation. The peptide sequence of MP-2 is Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu, and it is characterized by its stability and high specificity for immune targets (APExBIO, 2024).
Mechanistically, MP-2 exerts its effects by interacting with specific receptors on immune cells, leading to downstream modulation of cytokine networks, including the suppression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), while enhancing anti-inflammatory mediators (Kostyuk et al., 1993). This dual regulatory action positions MP-2 as a promising candidate for the management of immune-mediated disorders, including autoimmune diseases, inflammatory conditions, and as an adjunct in cancer immunotherapy.
[Related: NSC 681239]
Clinical Value and Applications [Related: mg132]
The clinical value of MP-2 lies in its ability to restore immune homeostasis in pathological conditions characterized by immune dysregulation. Unlike broad-spectrum immunosuppressants, MP-2 offers targeted modulation, minimizing the risk of global immunosuppression and associated complications such as increased susceptibility to infections.
Key clinical applications of MP-2 include:
- **Autoimmune Diseases:** MP-2 has demonstrated efficacy in preclinical models of rheumatoid arthritis and multiple sclerosis, where it reduces disease severity by dampening aberrant immune responses (Kostyuk et al., 1993; Gurevich et al., 1996).
- **Inflammatory Disorders:** By suppressing pro-inflammatory cytokines, MP-2 shows promise in the management of chronic inflammatory diseases, including inflammatory bowel disease and psoriasis (Ivanova et al., 2002).
- **Cancer Immunotherapy:** MP-2 can enhance the efficacy of existing immunotherapies by modulating the tumor microenvironment, reducing immune-related adverse events, and potentially overcoming resistance to checkpoint inhibitors (Gurevich et al., 1996).
- **Hematopoietic Recovery:** MP-2 has been studied for its role in promoting hematopoietic recovery following chemotherapy or bone marrow transplantation, attributed to its effects on bone marrow stromal cells and cytokine milieu (Kostyuk et al., 1993).
These applications underscore MP-2’s versatility as an immunomodulatory agent with broad translational potential.

Key Challenges and Pain Points Addressed
Current immunomodulatory therapies, including corticosteroids, biologics, and small molecule inhibitors, are often limited by significant side effects, non-specificity, and the risk of long-term immunosuppression (Barnes, 2011). These limitations drive the need for novel agents that can provide targeted immune modulation with improved safety profiles.
MP-2 addresses several key pain points:
- **Selective Immunoregulation:** MP-2’s mechanism allows for the fine-tuning of immune responses, reducing the risk of opportunistic infections and malignancies associated with broad immunosuppression.
- **Reduced Toxicity:** Preclinical studies indicate a favorable toxicity profile, with minimal off-target effects compared to traditional immunosuppressants (Ivanova et al., 2002).
- **Adjunctive Potential:** MP-2 can be combined with existing therapies to enhance efficacy and reduce adverse effects, particularly in refractory cases.
- **Restoration of Immune Balance:** In conditions where immune exhaustion or hyperactivation is present, MP-2 helps restore physiological immune function, potentially improving patient outcomes.
These attributes make MP-2 a compelling candidate for further clinical development in immune-mediated diseases.

Literature Review
A growing body of literature supports the immunomodulatory properties and therapeutic potential of MP-2 and related myelopeptides.
1. **Kostyuk et al. (1993, FEBS Letters):** This seminal study characterized the structure and biological activity of MP-2, demonstrating its ability to inhibit TNF-α and IL-1β production in vitro. The authors reported that MP-2 selectively modulates cytokine synthesis without affecting basal immune cell viability.
2. **Gurevich et al. (1996, International Journal of Immunopharmacology):** Investigated the effects of MP-2 in animal models of autoimmune disease. MP-2 administration resulted in significant attenuation of disease severity in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, suggesting its potential for treating demyelinating disorders.
3. **Ivanova et al. (2002, Immunology Letters):** Explored the anti-inflammatory effects of MP-2 in models of chronic inflammation. The study found that MP-2 reduced inflammatory cell infiltration and cytokine production in affected tissues, supporting its role in inflammatory disease management.
4. **Kostyuk et al. (1997, Biochemistry (Moscow)):** Provided further mechanistic insights, showing that MP-2 interacts with specific membrane receptors on mononuclear cells, leading to downstream signaling events that suppress pro-inflammatory gene expression.
5. **Barnes (2011, New England Journal of Medicine):** While not specific to MP-2, this review highlights the limitations of current immunosuppressive therapies, underscoring the need for novel agents like MP-2 that offer targeted modulation with fewer side effects.
6. **APExBIO Technology LLC (2024):** The product information page details the physicochemical properties, synthesis, and in vitro activity of MP-2, providing a foundation for further experimental and clinical studies.
Collectively, these studies establish a robust preclinical foundation for MP-2, supporting its continued investigation in clinical settings.

Experimental Data and Results
Experimental evaluation of MP-2 has been conducted in both in vitro and in vivo models, with a focus on its immunomodulatory and anti-inflammatory effects.
**In Vitro Studies:**
Kostyuk et al. (1993) demonstrated that MP-2, at nanomolar concentrations, significantly inhibited the production of TNF-α and IL-1β in lipopolysaccharide (LPS)-stimulated human mononuclear cells. The peptide did not affect cell viability or proliferation, indicating selective cytokine modulation.
**In Vivo Studies:**
Gurevich et al. (1996) administered MP-2 to mice with EAE and observed a marked reduction in clinical disease scores, demyelination, and inflammatory cell infiltration in the central nervous system. Similar findings were reported in models of rheumatoid arthritis, where MP-2 reduced joint swelling and histopathological damage.
Ivanova et al. (2002) evaluated MP-2 in a rat model of chronic colitis. MP-2 treatment led to decreased colonic inflammation, reduced levels of pro-inflammatory cytokines, and improved mucosal healing compared to controls.
**Toxicity and Safety:**
Across multiple studies, MP-2 exhibited a favorable safety profile, with no significant hematological, hepatic, or renal toxicity observed at therapeutic doses (Ivanova et al., 2002).
These experimental results provide compelling evidence for the immunomodulatory efficacy and safety of MP-2 in preclinical models.

Usage Guidelines and Best Practices
While MP-2 remains primarily a research tool, emerging data inform best practices for its experimental and potential clinical use.
**Dosage and Administration:**
- In vitro studies typically employ MP-2 at concentrations ranging from 10 nM to 1 μM, depending on cell type and assay conditions (Kostyuk et al., 1993).
- In vivo, effective doses in animal models range from 0.1 to 1 mg/kg, administered via intraperitoneal or subcutaneous injection (Gurevich et al., 1996).
**Formulation and Storage:**
- MP-2 is supplied as a lyophilized powder and should be reconstituted in sterile water or buffer prior to use.
- For long-term storage, aliquots should be kept at -20°C to maintain stability and activity (APExBIO, 2024).
**Experimental Considerations:**
- Appropriate controls, including vehicle and positive controls, are essential for interpreting immunomodulatory effects.
- Dose-response studies are recommended to identify optimal concentrations and minimize off-target effects.
- For translational studies, pharmacokinetic and pharmacodynamic profiling should be conducted to inform dosing regimens.
**Safety Precautions:**
- While preclinical studies indicate low toxicity, standard laboratory safety protocols should be followed.
- Monitoring for potential immunosuppression or hypersensitivity reactions is advised in animal studies.
These guidelines facilitate the reproducible and safe use of MP-2 in research settings, laying the groundwork for future clinical translation.

Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 29 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11578148